Barr Challenges Two 3M Process Patents On Raw Materials For Tambocor
Barr's manufacturing of flecainide does not infringe on two 3M process patents covering the raw materials for Tambocor, Barr maintained in its patent challenge for the anti-arrythmia agent.
You may also be interested in...
Barr is planning to launch a generic version of 3M's Tambocor (flecainide) in the fall following a favorable court decision in a patent infringement case.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011